Use access key #2 to skip to page content.
$4.64 -0.04 (-0.86%)
9/5/2008 4:00 PM

Dyax Corp. (DYAX)

CAPS Rating:
**

A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating DYAX

Add Stock to Watchlist

What the Community Thinks

Total Members

120 Outperforms
15 Underperforms
 

All-Stars

31 Outperforms
7 Underperforms
 

Wall Street

5 Outperforms
1 Underperforms
 

Members bullish on DYAX are also bullish on:

Members bearish on DYAX are also bearish on:

Ticker Tags

Micro Cap (4824), Biotechnology (294)
Suggest a tag

Dyax Corp. At A Glance

Current Price: $4.64
Last Trade Time: 9/5/2008 4:00 PM
Open: $4.64
Previous Close: $4.64
Daily Range: $4.49 - $4.81
52-Week Range: $2.80 - $5.35
Volume: 169,104
Market Cap: $281.40M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

DYAX VS S&P 500 (SPY)

DYAX 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for DYAX

More Headlines...

Top Bull Pitch

Recs

1

Dyax Corp. (DYAX)

Avatar biomedeng (87.30) Submitted: 12/31/07 8:06 PM

The thing to know about Dyax is that the HAE indication for DX-88 is mostly beneficial to get the drug approved for human use. Once DX-88 is approved, it is available for off label indications like CABG, currently in phase II trials. If a couple surgeons see better outcomes with DX-88 in their sol...More

Replies: 1 | Reply | Permalink

Top Bear Pitch

Recs

1

Dyax Corp. (DYAX)

Avatar majakblue (62.07) Submitted: 4/14/07 3:19 PM

Yeah, yeah, yeah, lets see if any of their candidates get past large scale phase III trials. Lets see if the patients have kidneys and liver left afterwards.

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 22 :   1 2 3 4 5 Next »

Show Pitch Replies

Recs

0

 (DYAX)

Avatar oldnbroke441 (91.48) Submitted: 7/22/08 10:27 AM : Outperform Start Price: $4.13 DYAX Score: 13.30

stoch MACD

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (DYAX)

Avatar ResearchLover (96.41) Submitted: 7/21/08 1:04 PM : Outperform Start Price: $4.01 DYAX Score: 17.02

I like the phase III results, healthy sales growth. Negative: there is a lot of volatility the price and I may just take my position off at any peak, not waiting for news.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (DYAX)

Avatar biomedeng (87.30) Submitted: 12/31/07 8:06 PM : Outperform Start Price: $3.87 DYAX Score: 35.94

The thing to know about Dyax is that the HAE indication for DX-88 is mostly beneficial to get the drug approved for human use. Once DX-88 is approved, it is available for off label indications like CABG, currently in phase II trials. If a couple surgeons see better outcomes with DX-88 in their solutions (and the trials are quite promising), the drug will become very popular very quickly regardless of what the on-label indications are.

Report this Post Replies: 1 | Reply | Permalink

Recs

0

 (DYAX)

Avatar doggetla (68.42) Submitted: 10/26/07 6:57 PM : Outperform Start Price: $4.50 DYAX Score: 22.28

great bio-tech partners - with lots of "magic beans" in pipeline

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (DYAX)

Avatar Dwaterman86 (< 20) Submitted: 10/04/07 3:39 PM : Underperform Start Price: $3.82 DYAX Score: -40.73

better off investing in magic beans

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 22 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 6 of 6  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackUBS 92.25 07/30/08 Outperform NS $4.29+8.16%-2.66%+10.82
TrackSusquehanna 44.29 01/11/08 Outperform NS $3.57+29.97%-11.62%+41.59
TrackCreditSuiss 95.02 10/03/07 Outperform NS $3.60+28.89%-19.11%+48.00
TrackJimCramer 82.62 04/16/07 Underperform 3W $5.65-17.88%-15.19%+2.69
TrackMorganJos < 20 03/15/07 Outperform NS $3.56+30.34%-10.47%+40.81
TrackInfiniumSec None 08/28/06 Outperform NS $3.40+36.47%-4.05%+40.52

Results 1 - 6 of 6  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners